Expects to end 2025 at ~2.8x. Says entering “exciting period” for biosimilar portfolio. Says has made “significant progress” with transformation program. Says set to deliver on 2027 targets. Comments taken from Q3 earnings conference call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA: